A Multivalent DNA Nanoparticle/Peptide Hybrid Molecular Modality for the Modulation of Protein–Protein Interactions in the Tumor Microenvironment
Open Access
- 25 April 2024
- journal article
- research article
- Published by Wiley in Advanced NanoBiomed Research
- Vol. 4 (7)
Abstract
Despite success in the treatment of some blood cancers and melanoma, positive response to immunotherapies remains disappointingly low in the treatment of solid tumors. The context of the molecular crosstalk within the tumor microenvironment can result in dysfunctional immune cell activation, leading to tumor tolerance and progression. Although modulating these protein–protein interactions (PPIs) is vital for appropriate immune cell activation and recognition, targeting nonenzymatic PPIs has proven to be fraught with challenges. To address this, a synthetic, multivalent molecular modality comprised of small interfering peptides precisely hybridized to a semirigid DNA scaffold is introduced. Herein, a prototype of this modality that targets the IL‐33/ST2 signaling axis, which is associated with tumor tolerance and immunotherapy treatment failure is described. Using peptides that mimic the specific high‐energy “hotspot” residues with which the IL‐33/ST2 coreceptor, IL‐1RAcP, interacts with the initial binary complex, this platform is shown to effectively bind IL‐33/ST2 with a KD of 110 nm. Additionally, this molecule effectively abrogates signal transduction in cell models at high nanomolar concentrations and is exquisitely selective for this complex over structurally similar PPIs within the same cytokine superfamily.Keywords
Funding Information
- National Institutes of Health (R21CA251015)
- Australian Research Council (FT190100645)
This publication has 51 references indexed in Scilit:
- Molecular conversion of MIG6 hotspot-3 peptide from the nonbinder to a moderate binder of HER2 by rational design of an orthogonal interaction system at the HER2–peptide interfaceBiophysical Chemistry, 2021
- Peptidomimetic-based antibody surrogate for HER2Acta Pharmaceutica Sinica B, 2021
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor DrugsJAMA Network Open, 2020
- Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancerCancer Immunology, Immunotherapy, 2020
- A ‘tile’ tale: Hierarchical self-assembly of DNA latticesApplied Materials Today, 2016
- Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cellsInternational Journal of Cancer, 2013
- Myeloid-derived suppressor cells in breast cancerBreast Cancer Research and Treatment, 2013
- ST2 deletion enhances innate and acquired immunity to murine mammary carcinomaEuropean Journal of Immunology, 2011
- DNA Tile Based Self‐Assembly: Building Complex NanoarchitecturesChemphyschem, 2006
- Determination of Rate and Equilibrium Binding Constants for Macromolecular Interactions Using Surface Plasmon Resonance: Use of Nonlinear Least Squares Analysis MethodsAnalytical Biochemistry, 1993